• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Oct. 21, 2016

View Archived Issues

Curing the sticker shock of new gene, cellular therapies

If lawmakers, industry and payers need any more motivation to reform the complex drug supply chain in the U.S., they have only to look at some of the potentially game-changing technologies coming down the pike. Read More

Ablynx shares fall as Abbvie passes on vobarilizumab in RA

DUBLIN – Shares in Ablynx NV dropped 18 percent Thursday morning on news that Abbvie Inc. decided not to trigger an option to take forward vobarilizumab in rheumatoid arthritis (RA). Vobarilizumab, an interleukin-6 receptor (IL-6R) inhibitor, recently demonstrated solid efficacy in a phase IIb head-to-head monotherapy trial against Actemra (tocilizumab, Roche Holding AG) and in a phase IIb combination trial with methotrexate. Read More

Tight FIT: Lone responder in Rigel placebo set turns phase III, but plan intact

What one analyst characterized as a "weird" placebo response in one patient was enough to skew the results for Rigel Pharmaceuticals Inc.'s second of two double-blind studies in its FIT phase III program with fostamatinib, an oral spleen tyrosine kinase inhibitor, in adults with chronic/persistent immune thrombocytopenia (ITP). Read More

'Gene therapy in a box' could allow point-of-care cell transduction

A new device greatly simplifies cell-based gene therapy, turning it from a clean room to a desktop operation. Read More

Theravance, Mylan herald positive top-line results in two phase III COPD studies

Theravance Biopharma Inc. and Mylan NV reported that revefenacin, a nebulized long-acting muscarinic antagonist (LAMA) for chronic obstructive pulmonary disease (COPD), met the primary endpoints in twin phase III studies, demonstrating statistically significant improvements from baseline over placebo in trough forced expiratory volume in one second (FEV1) after 12 weeks of dosing for each of two doses studied. Read More

Biosimilar pricing, delays in guidance rankle patients and providers

While the FDA and industry are gung-ho about the commitments they fine-tuned for the second rendition of the biosimilar user fee agreement (BsUFA), patient advocacy groups and health care providers aren't so happy with some of the measures, especially the proposed delays in guidance on interchangeability, naming and labeling. Read More

View from the U.S.: BIO chief defends industry amid pricing debate

LONDON – With pressure on drug pricing on the rise, Jim Greenwood, president of the U.S. Biotechnology Innovation Organization (BIO) was defending the industry's position in the U.K. yesterday, attending the Oxford University Union to debate the motion, "Big pharma prioritizes profit over patients." Read More

Financings

Puma Biotechnology Inc., of Los Angeles, priced an underwritten public offering of 3.75 million common shares at $40 apiece, a discount of 6.3 percent to the previous day's closing price of $42.75, seeking to raise $150 million. Read More

Other news to note

Vaxil Bio Ltd., of Toronto, said it R&D arm, Vaxil Biotherapeutics Israel and Rehovot, Israel-based Hadassah Medical Center have signed an agreement to work together on the company's immunotherapy platform, including its lead product, Immucin (MUC-1 peptide vaccine). Read More

In the clinic

Applied Genetic Technologies Corp., of Gainesville, Fla., said it filed an IND to conduct a phase I/II trial of its gene therapy candidate for the treatment of achromatopsia caused by mutations in the CNGA3 gene. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 10, 2025.
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 8, 2025
  • 3D rendering of a molecular glue mediating the interaction between two proteins

    With surface mimicry, molecular glues shed hairpin need

    BioWorld Science
    Degradation is a therapeutic strategy that could offer possibilities to get at currently undruggable target proteins. In targeted degradation, compounds induce...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe